menu
    • menu
    [{"orgOrder":0,"company":"RNAimmune","sponsor":"Terra Magnum Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"RV1730","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"RNAimmune \/ Terra Magnum Capital Partners","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune \/ Terra Magnum Capital Partners"},{"orgOrder":0,"company":"RNAimmune","sponsor":"Sirnaomics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Series A Financing","leadProduct":"RIM730","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RNAimmune","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"RNAimmune \/ Sirnaomics Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"RNAimmune \/ Sirnaomics Ltd."},{"orgOrder":0,"company":"RNAimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"mRNA-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RNAimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RNAimmune \/ Not Applicable"},{"orgOrder":0,"company":"RNAimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"RV-1730","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"RNAimmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune \/ Not Applicable"},{"orgOrder":0,"company":"RNAimmune","sponsor":"Sirnaomics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"RV-1770","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RNAimmune \/ Sirnaomics","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune \/ Sirnaomics"}]

    Find Clinical Drug Pipeline Developments & Deals by RNAimmune

    Menu

    RNAimmune

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RV-1770

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Sirnaomics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syn...

                            Details : RV-1770 is an innovative mRNA-based vaccine formulation with a unique AI-enhanced design using the sequence of the recent RSV clinical isolate. It demonstrated immunogenic responses and neutralization against both type A and B strains of RSV in preclinic...

                            Brand Name : RV-1770

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 18, 2023

                            Lead Product(s) : RV-1770

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Sirnaomics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RV-1730

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19...

                            Details : RV-1730 targets the SARS-CoV-2 variants and is being investigated as an effective vaccine booster with the potential to provide continued protection against COVID-19 infection.

                            Brand Name : RV-1730

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 27, 2023

                            Lead Product(s) : RV-1730

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting

                            Details : RNAimmune is focusing on pan-ras mRNA vaccine which elicits specific immune responses and inhibits tumor growth in the mouse model of colon cancer prolonging survival.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 07, 2023

                            Lead Product(s) : mRNA-based Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RIM730

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Sirnaomics

                            Deal Size : $27.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines

                            Details : The proceeds of thne financing will support the company to anticipate filing an IND with the FDA in the fourth quarter of 2022 to initiate a Phase I study to evaluate the safety, tolerability, and pharmacokinetics of RIM730.

                            Brand Name : RIM730

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 29, 2022

                            Lead Product(s) : RIM730

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Sirnaomics

                            Deal Size : $27.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            RNAimmune

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RV1730

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Terra Magnum Capital Partners

                            Deal Size : $2.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines

                            Details : The Company will use the proceeds to advance its Covid-19 vaccine (RV1730) program and neoantigen-based cancer vaccine programs.

                            Brand Name : RV1730

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 24, 2020

                            Lead Product(s) : RV1730

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Terra Magnum Capital Partners

                            Deal Size : $2.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth